Galectin (GALT) Investors Take Profit Following Pop on GR-MD-02 Patent News Monday
Tweet Send to a Friend
Up)
Galectin Therapeutics (Nasdaq: GALT) shares are pulling back Tuesday, following a strong 63.8 percent move higher Monday on the back of positive carbohydrate-based galectin inhibitor compound news.
Galectin ripped following reports it was issued U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies."
Shares are down over 8 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Galectin ripped following reports it was issued U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies."
Shares are down over 8 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Boeing's (BA) Flagship 787 Will Return to Service, United (UAL) to Make First Flight
- Amid Flaws, ING U.S. (VOYA) is Too Cheap to Pass On - Barron's
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
